-
Sector Analysis
Multiple Sclerosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Multiple Sclerosis market through 2034. GlobalData estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion...
-
Sector Analysis
Sleep Apnea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Sleep Apnea Therapeutics. In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of sleep apnea, representing a large portion of global cases. Currently, the sleep apnea market is saturated with generic drugs, and the sodium-dependent dopamine transporter (DAT) drug class dominates the approved innovator drugs landscape. The sleep apnea pipeline holds 27 molecules, with one asset in the pre-registration...
-
Sector Analysis
Nontuberculous Mycobacteria (NTM) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook. NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden,...
-
Sector Analysis
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
This report covers the 7 major markets and provides an Excel-based forecast model for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) market through 2032. GlobalData estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%. Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the...
-
Thematic Analysis
FDI Trends in Africa (2025)
Overall, Africa’s share of global FDI remains small, however, investment opportunities across the continent are increasingly viewed as a growth frontier, presenting competitive long-term benefits. Notably, Africa continues to offer higher average profitability on FDI relative to other regions, despite ample structural deficiencies fueling a high-risk premium; this is supported by the fact that the largest 40 companies in Africa have annualized returns of 12.9% in the last year. GlobalData’s FDI Team expects FDI to diversifyaway from traditional, extractive industries...
-
Sector Analysis
Multiple Sclerosis Epidemiology Analysis and Forecast to 2034
Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremors, muscle spasms, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people aged 15–60 years. The diagnosis of MS depends upon patients’ symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently,...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. For the treatment of MG, most patients will be prescribed either corticosteroids or acetylcholinesterase inhibitors, with the corticosteroid prednisone and the acetylcholinesterase inhibitor pyridostigmine being the treatments most prescribed by physicians. When standard treatments fail, monoclonal antibodies are prescribed, offering more targeted, aggressive therapy. The MG market across the 7MM was valued at $6.1 billion in 2024 and is expected to grow...
-
Sector Analysis
Pulmonary Arterial Hypertension (PAH) Epidemiology Analysis and Forecast to 2034
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder of unknown cause, characterized by vascular proliferation and remodelling of the small pulmonary arteries. A significant number of risk factors and pathophysiological conditions are suspected to play roles in disease progression (Humbert et al., 2004, 2010; Simonneau et al., 2004; Bonnet et al., 2017). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and can lead to right ventricular overload...
-
Thematic Analysis
Outsourcing in Clinical Trials (OCT) Europe: Barcelona, Spain 29-30 April 2025
The Outsourcing in Clinical Trials Europe 2025 conference took place in Barcelona, Spain, April 29–30. The meeting provided an opportunity for clinicians, pharmaceutical company executives, trial software vendors, technology experts, and contract research and manufacturing organization executives to discuss the latest trends and challenges in the clinical trials space in Europe. In this report, GlobalData provides expert insights into key themes relevant to the clinical trials sector, with a focus on elements that drive successful operations in Europe. Through several...
-
Sector Analysis
Mucopolysaccharidosis III (Sanfilippo Syndrome) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis III (Sanfilippo Syndrome) Therapeutics. In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of MPS III, representing a large portion of global cases. Currently, there is no cure for MPS III, and no disease-modifying therapies are available. The MPS III pipeline holds 24 molecules, with only one asset in the pre-registration stage. Over the past decade, 29 clinical...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.